Development and Analytical Validation of an In-House Quantitative Indirect ELISA for Detection of IgG Antibodies Against SARS-CoV-2 Spike Protein: A Pilot Study

When a virus like SARS-CoV-2 enters the human body, the immune system responds by building a specialized defense force. Among these defenders are Y-shaped proteins called antibodies, which act like molecular tags that stick specifically to the virus, marking it for destruction. Scientists can find these antibodies in a person's blood long after an infection has cleared, providing a historical record of who has been exposed. This ability to look back in time is called serology, and it is essential for understanding how widespread an infection has been, how long immunity lasts, and how well vaccines are working. However, for many countries, the tools needed to perform these tests are expensive, imported, and often unavailable when supply chains break down. This creates a dangerous gap in global health security, leaving nations unable to track the virus's spread or prepare for future outbreaks without relying on outside help.

In response to this challenge, a team of researchers at the Institut Pasteur in Morocco and the Mohammed VI Polytechnic University set out to build their own version of a critical diagnostic tool from the ground up. They focused on creating a test that could measure the amount of IgG antibodies—those long-lasting defenders—specifically targeting the spike protein of the SARS-CoV-2 virus. The spike protein is the part of the virus that allows it to enter human cells, making it the primary target for the immune system's response. The researchers did not just want a simple yes-or-no test; they wanted a quantitative method, one that could measure exactly how much antibody was present in a sample. This precision is vital for comparing immune responses across different populations and over time. Their goal was to prove that a high-quality, reliable laboratory test could be developed locally, using standard equipment and materials, to reduce dependence on foreign commercial kits.

The team began by carefully tuning the conditions of their test, which is known as an enzyme-linked immunosorbent assay, or ELISA. Imagine a flat tray with tiny wells, like a miniature egg carton, where the virus's spike protein is glued down to act as a trap. The researchers tested different amounts of this protein and different ways of diluting the blood samples to find the perfect balance. They discovered that using a specific, moderate amount of the spike protein and diluting the blood one hundred times produced the clearest and most accurate results. If they used too much protein, the signal became saturated and lost precision; if they diluted the blood too much, weak immune responses were missed. By finding this sweet spot, they ensured the test could detect both strong and weak antibody levels without confusion.

To make the test quantitative, the scientists created their own internal ruler. They mixed together blood samples from six people who had recovered from COVID-19 to create a standard reference pool. By testing this pool at various dilutions, they established a calibration curve, a straight line that allowed them to convert the raw color change in the test into a specific number representing the concentration of antibodies. This approach meant that every time they ran the test, they could express the results in arbitrary units per milliliter, providing a consistent way to measure immune response levels. The linearity of this curve was exceptionally strong, meaning the test responded predictably across the entire range of antibody concentrations they expected to see.

The researchers then subjected their new test to rigorous checks to ensure it was reliable and precise. They ran the same samples multiple times on the same day and on different days to see if the results stayed consistent. The variations they found were extremely small, well within the strict limits required for medical diagnostics. They also calculated the lowest amount of antibody the test could reliably detect, confirming that it was sensitive enough to find even low levels of immune response. These analytical limits were far below the signals produced by actual positive cases, ensuring that the test would not miss genuine infections. The data showed that the test was robust, reproducible, and capable of distinguishing between positive and negative samples with high confidence.

Finally, the team tested their method on a small, independent group of twenty blood samples to see how well it performed in a real-world scenario. Ten of these samples came from people who had a confirmed active infection, and ten came from people who had been tested before the pandemic existed. The test correctly identified nine out of ten infected individuals and nine out of ten uninfected individuals. While one infected person was missed, likely because their immune response was too weak to be detected at that time, and one uninfected person showed a borderline result, the overall performance was strong. The test successfully separated the two groups with a high degree of accuracy, demonstrating that a locally developed, in-house test could achieve results comparable to commercial alternatives.

This work represents more than just a new test for one virus; it establishes a complete, reproducible blueprint for building diagnostic tools in resource-limited settings. By validating their method against international standards for precision and detection, the researchers have shown that national laboratories can develop their own capacity to monitor infectious diseases. This independence is crucial for pandemic preparedness, allowing countries to respond quickly to new threats without waiting for imported supplies. While the study was a pilot with a small number of samples, the results suggest that this approach is feasible and effective. The next steps will involve testing the method on larger, more diverse groups of people, including those who have been vaccinated or infected with different variants, to fully confirm its utility for long-term public health surveillance.